Off-Label Communication Growth: Could FDA Afford To Police It?
Another user fee for the US drug agency could help pay for research of off-label uses, but lack of resources could be a regulatory problem.
You may also be interested in...
Off-Label Communication: Pfizer Highlights Burdens Of FDA Policy
Seeking relaxation of US agency restrictions, Pfizer cites three examples where company delayed or decided against distributing medically relevant information beyond the product labeling; PhRMA survey shows almost half of all requests for information by prescribers and payers relate to off-label use.
Payers Want Access To US FDA's Pre-Submission Meetings
As sponsors push for more access to physicians, payers hope to be able to gather more pre-approval information about drugs – like they now can with devices – for budgeting and patient access.
Keep Limits On Off-Label Promotion, Consumers And Patients Say
Prescribers can get information they need through continuing education programs and scientific conferences, non-industry stakeholders tell US FDA during second day of meeting on manufacturer communications for unapproved uses.